NCT05971862View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SKI-G-801 in Patients With Advanced Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 25, 2022

Primary Completion Date

April 23, 2024

Study Completion Date

October 4, 2024

Conditions
Advanced Solid Tumor
Interventions
DRUG

SKI-G-801

Oral SKI-G-801(Denfivontinib) will be daily administered based on dose level.

Trial Locations (3)

03722

Yonsei University College of Medicine Severance Hospital, Seoul

05505

Asan Medical Center, Seoul

06351

Samsung Medical Center, Seoul

Sponsors

Lead Sponsor

Oscotec Inc.
All Listed Sponsors
lead

Oscotec Inc.

INDUSTRY

NCT05971862 - A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SKI-G-801 in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter